Bacitracin zinc antibiotic ointment is a topical antimicrobial preparation combining bacitracin, a polypeptide antibiotic, with zinc salts for enhanced stability. It works by inhibiting bacterial cell wall synthesis, targeting gram-positive organisms such as Staphylococcus aureus and Streptococcus pyogenes. In the United Kingdom, bacitracin zinc ointment is not widely available through the NHS or standard community pharmacies. UK prescribing practices favour licensed alternatives such as fusidic acid or mupirocin. Bacitracin preparations are not listed in the British National Formulary (BNF) and may only be obtained as unlicensed 'special' medicines through specialist importers or private prescriptions. Healthcare professionals should follow NICE guidance on appropriate topical antimicrobial use and be familiar with UK-licensed alternatives.

What Is Bacitracin Zinc Antibiotic Ointment?

Bacitracin zinc antibiotic ointment is a topical antimicrobial preparation containing bacitracin, a polypeptide antibiotic, combined with zinc salts to enhance stability and skin tolerability. Bacitracin works by inhibiting bacterial cell wall synthesis, specifically targeting gram-positive organisms such as Staphylococcus aureus and Streptococcus pyogenes. The zinc component primarily serves as a stabilising agent in the pharmaceutical formulation.

In the United Kingdom, bacitracin zinc ointment is not widely available as a standalone product through the NHS or standard community pharmacies. Whilst it remains a common over-the-counter antibiotic in North America, UK prescribing practices favour alternative topical antibiotics such as fusidic acid or mupirocin, which are licensed medicinal products in the UK. Bacitracin preparations are not listed in the British National Formulary (BNF) as licensed topical antibacterials and may only be obtained as unlicensed 'special' medicines through specialist importers or private prescriptions, requiring specific clinical justification.

The ointment is typically formulated in a petroleum-based vehicle, creating an occlusive barrier that maintains wound moisture whilst delivering the antibiotic directly to the affected area. This formulation is particularly suited to minor cuts, grazes, and superficial skin infections where bacterial colonisation poses a risk of delayed healing. However, clinicians should note that bacitracin has a relatively narrow spectrum of activity, and its use should be guided by the nature and severity of the wound, patient allergy history, and local antimicrobial stewardship guidelines. Healthcare professionals practising in Britain should be familiar with UK-licensed alternatives and follow NICE guidance on appropriate use of topical antimicrobials.

How to Use Bacitracin Zinc Ointment Safely

When bacitracin zinc ointment is used, proper application technique is essential to maximise therapeutic benefit whilst minimising the risk of adverse effects or treatment failure. Before application, the affected area should be thoroughly cleansed with mild soap and water or an appropriate wound cleanser, then gently patted dry with a clean towel or sterile gauze. Hands must be washed before and after application to prevent cross-contamination and secondary infection.

A thin layer of ointment should be applied directly to the affected skin, typically two to three times daily, or as directed by a healthcare professional. The amount used should be sufficient to cover the wound or affected area without excessive build-up, as over-application does not enhance efficacy and may increase the risk of sensitisation. If desired, the treated area may be covered with a sterile dressing, particularly for wounds in areas subject to friction or contamination. Modern wound care principles favour maintaining a moist healing environment, though excessive moisture (maceration) should be avoided.

Duration of treatment should generally not exceed seven days for minor wounds without medical supervision, in line with antimicrobial stewardship principles. If symptoms worsen, fail to improve within 48–72 hours, or if signs of spreading infection develop (increased redness, warmth, swelling, purulent discharge, or fever), patients should be advised to contact their GP promptly. Prolonged use beyond one week increases the risk of contact sensitisation and may promote antimicrobial resistance.

Bacitracin zinc ointment should not be applied to deep puncture wounds, animal bites, serious burns, or large areas of broken skin without medical guidance. It is intended for external use only and must be kept away from the eyes, mouth, and mucous membranes. If accidental contact occurs, the area should be rinsed thoroughly with water. The product should be stored at room temperature, away from direct heat and sunlight, and the tube should be recapped immediately after use to minimise contamination. Pregnant or breastfeeding women should consult their healthcare provider before using any unlicensed topical antibiotic preparation.

Possible Side Effects and Allergic Reactions

Whilst bacitracin zinc ointment is generally well-tolerated when used appropriately, adverse effects can occur, ranging from mild local reactions to serious hypersensitivity responses. The most commonly reported side effect is contact dermatitis, which may manifest as localised itching, redness, rash, or mild burning sensation at the application site. These reactions are typically mild and resolve upon discontinuation of the product. However, contact sensitisation to bacitracin has been increasingly recognised, with studies in patch-test clinic populations suggesting sensitisation rates of approximately 3–10%, particularly in those with chronic wounds or repeated exposure.

Allergic contact dermatitis represents a more significant concern and is a Type IV delayed hypersensitivity reaction. Patients may develop eczematous changes, vesiculation, or spreading erythema extending beyond the treatment area, typically appearing 24–72 hours after application. This reaction necessitates immediate discontinuation of bacitracin and may require treatment with topical corticosteroids. Healthcare professionals should maintain a high index of suspicion for contact allergy, particularly in patients whose wounds appear to worsen despite treatment or who develop new skin changes during therapy. Recurrent reactions may warrant dermatology referral for patch testing.

Rare but serious adverse effects include anaphylactic reactions, though these are exceptionally uncommon with topical use. Symptoms of anaphylaxis include difficulty breathing, facial or throat swelling, rapid pulse, dizziness, or widespread urticaria. This constitutes a medical emergency requiring immediate activation of emergency services (999) and administration of intramuscular adrenaline if available and the responder is trained in its use.

Nephrotoxicity and ototoxicity have been reported with systemic bacitracin administration but are not expected with appropriate topical use on intact or minimally broken skin. However, application to large areas of denuded skin should be avoided due to potential systemic absorption. Patients should be counselled to report any unexpected symptoms, though such effects would be highly unusual with topical formulations. If any concerning symptoms develop, patients should seek medical advice promptly from their GP or NHS 111 service. Suspected adverse reactions can be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

Alternatives to Bacitracin Zinc Ointment in the UK

Given the limited availability of bacitracin zinc ointment in the United Kingdom, healthcare professionals and patients should be familiar with UK-licensed alternatives that are readily accessible through the NHS and community pharmacies. The choice of topical antibiotic should be guided by the nature of the wound, suspected or confirmed pathogens, patient allergy history, and local antimicrobial stewardship guidelines.

Fusidic acid (available as Fucidin® or generic preparations) is a first-line topical antibiotic widely used in the UK for superficial skin infections. It demonstrates excellent activity against staphylococci and streptococci, the most common causative organisms in minor skin infections. Fusidic acid is available as a 2% cream or ointment and is typically applied two to three times daily for up to seven days. NICE guidance supports its use for impetigo, though concerns about emerging resistance have led to recommendations for judicious use and adherence to short treatment courses.

Mupirocin (Bactroban®) is another highly effective topical antibiotic with potent activity against gram-positive bacteria, including meticillin-resistant Staphylococcus aureus (MRSA). It is particularly valuable for treatment of localised skin infections. Mupirocin 2% ointment is applied two to three times daily for up to ten days. For MRSA nasal decolonisation, a specific nasal formulation (Bactroban Nasal® 2%) should be used according to local protocols. Due to its importance in managing resistant organisms, mupirocin should be reserved for confirmed or suspected staphylococcal infections rather than routine prophylaxis, in line with antimicrobial stewardship principles.

For minor wounds and abrasions where infection risk is low, simple wound care with thorough cleansing and appropriate dressings may be sufficient without antibiotic use. NICE recommends that topical antibiotics should not be used routinely for wound prophylaxis, as this practice may promote resistance without clear clinical benefit. Antiseptic preparations such as chlorhexidine or povidone-iodine may be considered for wound cleansing when clinically indicated, though routine use is not recommended.

Combination products such as neomycin with hydrocortisone are available but should be used cautiously due to the high sensitisation potential of neomycin (reported in up to 10% of patients with chronic wounds). For patients with confirmed bacitracin allergy, cross-reactivity with other antibiotics is uncommon, making fusidic acid or mupirocin suitable alternatives. Patients requiring topical antibiotics should be advised to complete the prescribed course, monitor for signs of treatment failure or adverse effects, and consult their GP if symptoms persist beyond 48–72 hours or worsen during treatment.

Frequently Asked Questions